New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
In a multicenter cohort of patients with newly diagnosed pulmonary hypertension, increased risk for mortality among African Americans was no longer observed after adjusting for insurance status.
Precision medicine is increasingly being utilized in oncology. Aurora Health Care has implemented Syapse software to integrate molecular data into the electronic health record to accommodate precision medicine findings.
This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
The pandemic of type 2 diabetes mellitus requires implementation of multifactorial interventions by clinicians for individual patients and policy makers for the health of the general public.
This study determined that ICD-9 codes 433.X1, 434.XX, and V12.54 had positive predictive values >90%, and may be used to focus care on stroke patients.
Medical utilization profiles of commercially insured members with opioid-related disorders differ depending on the code used to document the initial diagnosis in administrative claims.
Additional training opportunities for primary care physicians and better use of ancillary services may be needed to further improve care for chronic pain patients.
An asthma disease management program reduced medical services utilization for urban children and had a potentially positive return on investment for Medicaid managed care plans.
This analysis of antiosteoporosis therapy shows that 75% of patients have inadequate drug coverage and that adherence is strongly associated with age and administration regimen.
We determine a specialist physician phenotype responsive to financial incentives that may be leveraged to identify physicians and markets well-suited for participation in alternative payment models.
State-level estimates of the number of people treated for cancer and the average cost of their treatment by state from 2010 through 2020.